Mydecine Innovations Group Inc.
MYCO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.64M | 125.30K | -1.82M | -2.36M | -9.15M |
| Total Depreciation and Amortization | -- | -- | -- | -- | 0.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -341.00K | 5.10K | 539.70K | 559.90K | 3.98M |
| Change in Net Operating Assets | -1.31M | -137.30K | 1.27M | 1.77M | 4.91M |
| Cash from Operations | -9.10K | -6.80K | -7.00K | -26.40K | -257.50K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | -- | -- | -- | -- | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | 110.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 283.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | 288.90K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.10K | -6.80K | -7.00K | -26.40K | 31.30K |